Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outpatient vs inpatient treatment Short‐term all‐cause mortality · people with low‐risk acute pulmonary embolism Outpatient versus inpatient treatment for acute pulmonary embolism (2022) · Cochrane | no estimate extracted | 2 studies · 453 participants | Low |
Outpatient vs inpatient treatment Short‐term all‐cause mortality · people with low‐risk acute pulmonary embolism Outpatient versus inpatient treatment for acute pulmonary embolism (2022) · Cochrane | RR 0.33 [0.01, 7.98] | 2 studies · 453 participants | Low |
Outpatient vs inpatient treatment Long‐term all‐cause mortality · people with low‐risk acute pulmonary embolism Outpatient versus inpatient treatment for acute pulmonary embolism (2022) · Cochrane | RR 0.98 [0.06, 15.58] | 2 studies · 451 participants | Low |
Outpatient vs inpatient treatment Major bleeding · people with low‐risk acute pulmonary embolism Outpatient versus inpatient treatment for acute pulmonary embolism (2022) · Cochrane | RR 4.91 [0.24, 101.57] | 2 studies · 445 participants | Low |
Outpatient vs inpatient treatment Major bleeding · people with low‐risk acute pulmonary embolism Outpatient versus inpatient treatment for acute pulmonary embolism (2022) · Cochrane | RR 6.88 [0.36, 132.14] | 2 studies · 445 participants | Low |
Outpatient vs inpatient treatment Minor bleeding · people with low‐risk acute pulmonary embolism Outpatient versus inpatient treatment for acute pulmonary embolism (2022) · Cochrane | RR 1.08 [0.07, 16.79] | 1 study · 106 participants | Low |
Outpatient vs inpatient treatment Recurrent PE · people with low‐risk acute pulmonary embolism Outpatient versus inpatient treatment for acute pulmonary embolism (2022) · Cochrane | RR 2.95 | 2 studies · 445 participants | Low |
Corticosteroids vs no corticosteroid use Incidence of coronary artery abnormalities · children diagnosed with Kawasaki disease Corticosteroids for the treatment of Kawasaki disease in children (2022) · Cochrane | OR 0.32 [0.14, 0.75] | 8 studies · 986 participants | Moderate |
Corticosteroids vs no corticosteroid use Incidence of any serious adverse effects attributable to the administration of corticosteroids · children diagnosed with Kawasaki disease Corticosteroids for the treatment of Kawasaki disease in children (2022) · Cochrane | no estimate extracted | 6 studies · 737 participants | Moderate |
Corticosteroids vs no corticosteroid use Mortality (all‐cause) · children diagnosed with Kawasaki disease Corticosteroids for the treatment of Kawasaki disease in children (2022) · Cochrane | no estimate extracted | 8 studies · 1075 participants | Moderate |
Corticosteroids vs no corticosteroid use Duration of clinical symptoms: fever and rash (days) · children diagnosed with Kawasaki disease Corticosteroids for the treatment of Kawasaki disease in children (2022) · Cochrane | no estimate extracted | 3 studies · 290 participants | Low |
Corticosteroids vs no corticosteroid use Time for laboratory parameters to normalise: CRP, ESRe (days) · children diagnosed with Kawasaki disease Corticosteroids for the treatment of Kawasaki disease in children (2022) · Cochrane | no estimate extracted | 1 study · 178 participants | Moderate |
Corticosteroids vs no corticosteroid use Length of hospital stay (days) · children diagnosed with Kawasaki disease Corticosteroids for the treatment of Kawasaki disease in children (2022) · Cochrane | no estimate extracted | 2 studies · 119 participants | Moderate |
Corticosteroids vs no corticosteroid use Longer term (> 1 year after disease onset) coronary morbidity (non‐aneurysmal) · children diagnosed with Kawasaki disease Corticosteroids for the treatment of Kawasaki disease in children (2022) · Cochrane | no estimate extracted | NR | No studies |
Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone Recurrent VTE · people requiring treatment for acute DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | 1 study · 500 participants | Very low |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone Mortality ‐ early and intermediate · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | 1 study · 224 participants | Very low |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone Post‐thrombotic syndrome · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone Adverse events · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | 1 study · 224 participants | Very low |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo Recurrent VTE ‐ early, intermediate and long term · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | RR 0.65 [0.43, 0.96] | 4 studies · 901 participants | Low |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo Major bleeding · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | RR 0.98 [0.29, 3.34] | 1 study · 583 participants | Moderate |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo Pulmonary embolism (fatal/non‐fatal) · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | RR 0.52 [0.23, 1.14] | 1 study · 583 participants | Moderate |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo Mortality ‐ intermediate and long term · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | RR 0.48 [0.21, 1.06] | 3 studies · 649 participants | Moderate |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo Post‐thrombotic syndrome · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo Adverse events · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | RR 1.57 [0.34, 7.19] | 2 studies · 621 participants | Moderate |
Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone Major bleeding · people requiring treatment for acute DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | 1 study · 500 participants | Very low |
Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone Pulmonary embolism · people requiring treatment for acute DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | 1 study · 500 participants | Very low |
Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone Mortality ‐ early and intermediate · people requiring treatment for acute DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | 1 study · 500 participants | Very low |
Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone Post‐thrombotic syndrome · people requiring treatment for acute DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | RR 0.74 [0.61, 0.91] | 1 study · 500 participants | Very low |
Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone Adverse events · people requiring treatment for acute DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | RR 2.88 [1.06, 7.8] | 1 study · 500 participants | Very low |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone Recurrent VTE ‐ early and intermediate · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | RR 0.12 [0.05, 0.34] | 1 study · 224 participants | Very low |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone Major bleeding · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | 1 study · 224 participants | Very low |
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone Pulmonary embolism · people requiring treatment for chronic DVT Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane | no estimate extracted | 1 study · 224 participants | Very low |
Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive)… (2022) · Cochrane | no estimate extracted | 1 study · 59 participants | Ungraded |
Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive)… (2022) · Cochrane | OR 0.31 [0.01, 7.96] | 1 study · 59 participants | Very low |
Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation Treatment‐associated major haemorrhage ( · people with intermediate‐risk (submassive) APE Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive)… (2022) · Cochrane | no estimate extracted | 1 study · 59 participants | Ungraded |
Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation Treatment‐associated minor haemorrhage ( · people with intermediate‐risk (submassive) APE Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive)… (2022) · Cochrane | OR 3.11 [0.3, 31.79] | 1 study · 59 participants | Very low |
Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation Recurrent APE requiring retreatment or change to a different APE treatment ( · people with intermediate‐risk (submassive) APE Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive)… (2022) · Cochrane | no estimate extracted | 1 study · 59 participants | Ungraded |
Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation Length of hospital stay (days) · people with intermediate‐risk (submassive) APE Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive)… (2022) · Cochrane | no estimate extracted | 1 study · 59 participants | Very low |
Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation Quality of life  · people with intermediate‐risk (submassive) APE Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive)… (2022) · Cochrane | no estimate extracted | 1 study · 59 participants | Ungraded |
Avoralstat vs placebo Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 0.99 [0.92, 1.06] | 1 study · 110 participants | Moderate |
Berotralstat vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
Berotralstat vs placebo or active control Serious adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 0.77 [0.02, 24.03] | 3 studies · 128 participants | Low |
Berotralstat vs placebo or active control Quality of lifeAngioedema Quality of Life scale(lower score is better)(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 3 studies · 130 participants | Moderate |
Berotralstat vs placebo or active control DisabilityStandardised mean difference (lower is better) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 2 studies · 50 participants | Low |
Berotralstat vs placebo or active control Adverse events(during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 1.03 [0.88, 1.22] | 3 studies · 128 participants | Moderate |
C1 esterase inhibitor vs placebo or active control Risk of HAE attacks (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 0.29 [0.16, 0.5] | 1 study · 43 participants | Low |
C1 esterase inhibitor vs placebo or active control Change in number of HAE attacks (per week) · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 45 participants | Low |
C1 esterase inhibitor vs placebo or active control Mortality (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | NR | No studies |
C1 esterase inhibitor vs placebo or active control Serious adverse events (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | RR 0.34 [0.01, 8.14] | 1 study · 44 participants | Very low |
C1 esterase inhibitor vs placebo or active control Quality of lifestandardised mean difference (lower is better) (during · children or adults with Types I or II HAE Interventions for the long‐term prevention of hereditary angioedema attacks (2022) · Cochrane | no estimate extracted | 1 study · 36 participants | Low |